FOLR1 and peritoneum cancer: The U.S. Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx, an antibody-drug conjugate, on 22 March 2024, for treating adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer [6].